Key Highlights

  • Long-range targets include a 5–7% organic sales CAGR and $300 million of savings.
  • The FY26 non-GAAP EPS outlook was reaffirmed at the upper end of $11.15–$11.45.
  • UBS resumed coverage at Buy with a $357 target.
  • Q3 results are expected on November 4.

Charles River Laboratories International, Inc. (NYSE:CRL) has a market capitalisation of about $14.4 billion. Following a September 24 Investor Day, several analysts raised targets, and UBS resumed coverage at Buy with a $357 target. Investors may be assessing whether the long-range targets are credible.

Latest Company Context

At the Investor Day the company set out a refreshed strategy, with long-range targets of a 5% to 7% organic sales CAGR, margins of roughly 24%, double-digit EPS growth and $300 million of cost savings by 2030. It reaffirmed its FY26 non-GAAP EPS outlook, reported at the upper end of $11.15 to $11.45, with revenue growth at the upper end of 0% to 1% and a non-GAAP operating margin of 21% to 21.3%. Trailing revenue is $4.00 billion, down 0.7%, and trailing GAAP results show a net loss of $238 million. Recent news includes a partnership with Autolomous on lab execution systems and rapid cell banking programmes. Q3 timing was announced October 9.

Key Business Drivers

Charles River supplies research models, discovery and safety assessment services to pharma and biotech, so demand follows biopharma funding and R&D spending. Flat revenue contrasts with higher targeted growth, so investors may focus on bookings and cost savings. Eighteen analysts have a Buy consensus and an average target of about $310.5; Jefferies, Argus, BofA and others lifted targets. No dividend is listed.

What Investors Should Watch

Q3 results are expected on November 4, where investors may watch bookings, book-to-bill, and whether the FY26 range holds. Delivery on the $300 million savings plan, biotech funding conditions, and regulatory shifts toward non-animal testing methods are potential swing factors, as are new technology partnerships.

Ambitious Multi-Year Goals Set Against Flat Near-Term Revenue

Charles River has set ambitious multi-year goals while reaffirming a near-term outlook. Bookings and progress on the $300 million savings plan are the measures of whether demand supports the plan.